ReviewOncology letters2026
Chrono-immunotherapy in genitourinary oncology: From emerging evidence to clinical translation (Review).
Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The intersection of immunotherapy and circadian biology represents a promising translational frontier in genitourinary (GU) oncology. Immunotherapy has reshaped the treatment landscape and markedly influenced patient outcomes in renal cell carcinoma (RCC) and urothelial carcinoma (UC), yet therapeutic responses remain variable, highlighting the necessity for strategies that can further enhance therapeutic efficacy. Notably, the circadian regulation of immune cell trafficking plays a central role in immune function and tumor biology. Retrospective analyses have suggested that earlier time-of-day administration of immunotherapy improves patient outcomes in RCC and UC. To facilitate the translation of chrono-immunotherapy from a theoretical concept to a clinical standard for patients, the present review assesses the biological rationale behind chronotherapy, summarizes clinical and scientific evidence regarding its therapeutic potential and provides a method for the prospective validation of chronotherapy in GU oncology. The present review also identifies current limitations in chrono-immunotherapy data and proposes potential solutions to validate this data and guide its translation into clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.